Substance abuse and pharmacy practice: What the community pharmacist needs to know about drug abuse and dependence

Harm Reduction Journal

Volumn 1, Issue , 2004, Pages

  Tommasello, Anthony C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; ALCOHOL; AMFEBUTAMONE; AMPHETAMINE; ANESTHETIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CAFFEINE; CANNABIS; CENTRAL DEPRESSANT AGENT; CENTRAL STIMULANT AGENT; COCAINE; DIAMORPHINE; DISULFIRAM; ILLICIT DRUG; LEVACETYLMETHADOL; LYSERGIDE; METHADONE; NALTREXONE; NARCOTIC AGENT; NICOTINE; NICOTINE GUM; OPIATE; PHENETHYLAMINE DERIVATIVE; PSYCHEDELIC AGENT; SOLVENT;

ALCOHOLISM; CANNABIS ADDICTION; COCAINE DEPENDENCE; COMMUNITY CARE; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFICACY; DRUG USE; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH PRACTITIONER; HUMAN; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL RESEARCH; NARCOTIC DEPENDENCE; NEUROCHEMISTRY; NICOTINE REPLACEMENT THERAPY; OPIATE ADDICTION; PARENT COUNSELING; PATIENT COUNSELING; PATIENT REFERRAL; PHARMACEUTICAL CARE; RESOURCE MANAGEMENT; REVIEW; RISK ASSESSMENT; SCREENING TEST; SUBSTANCE ABUSE; TEAMWORK; TOBACCO DEPENDENCE; TREATMENT INDICATION; WITHDRAWAL SYNDROME;

EID: 4243055990     PISSN: 14777517     EISSN: None     Source Type: Journal    
DOI: 10.1186/1477-7517-1-3     Document Type: Review

References (52)

1. Haack MR, Hoover A Jr: Strategic Plan for Interdisciplinary Faculty Development: Arming the Nation's Health Professional Workforce for a New Approach to Substance Use Disorders. Substance Abuse 2002, 23(3):1-21.
2. Dole EJ, Tommasello A: Recommendations for Implementing Effective Substance Abuse Education in Pharmacy Practice. Substance Abuse 2002, 23(3):263-271.
3. Leshner AI: Addiction is a Brain Disease and It Matters. Science 1997, 278(5335):45-47.
4. Miller WR, Walters ST, Bennett ME: How effective is alcoholism treatment in the United States? J Stud Alcohol 2001, 62:211-220.
5. O'Malley PM, Johnston LD, Bachman JG: Adolescent Substance Abuse Epidemiology and Implications for Public Policy. Pediatric Clinics of North America 1995, 42(2):241-260.
6. Dabney DA: Onset of Illegal use of Mind-Altering or Potentially Addictive Prescription Among Pharmacists. Journal of the American Pharmaceutical Association 2001, 41(2):392-400.
7. The Children's Health Act of 2000 Title 35, Section 3501 the Drug Addiction Treatment Act of 2000. H.R. 4365 of the 106th Congress, January 2000. .
8. Smith DE, Seymour R: A Clinical Approach to the Impaired Health Professional. Int J Addict 1985, 20(7):13-22.
9. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. Washington D.C., American Psychiatric Association 41994.
10. Grant BF, Dawson DA: Alcohol and Drug Use, Abuse, and Dependence: Classification, Prevalence, and Comorbidity. in Addictions A Comprehensive Guidebook Volume Chapter 1. Edited by: McCrady BS, Epstein EE. Oxford University Press; 1999.
11. Hyman SE: Initiation and Adaptation: A Paradigm for Understanding Psychotropic Drug Action. American Journal of Psychiatry 1996, 153:151-162.
12. Schuckit MA: Biological Vulnerability to Alcoholism. J Consult Clin Psychol 1987, 55(30):1-9.
13. Grant BF, Peterson LA, Dawson DS, Chou SP: Source and accuracy statement for the National Longitudinal Alcohol Epidemiological Survey. Rockville, MD. National Institute on Alcohol Abuse and Alcoholism 1994.
14. Anthony JC, Warner LA, Kessler RC: Comparative epidemiology of dependence on tobacco, alcohol, controlled substances, and inhalants: Basic findings from the National Comorbidity Survey. Exp Clin Psychopharmacol 1994, 2:244-268.
15. Rosenberg MF, Anthony JC: Early manifestations of cannabis dependence in a community sample. Drug and Alcohol Dependence 2001, 64:123-131.
16. McGinnis J, Michael F, William H: Actual Causes of Death in the United States. JAMA 1993, 270(18):2207-2212.
17. ASHP position statement on pharmaceutical care. Am J Hosp Pharm 1993, 50:1720-1723.
18. Conlan MF: APhA forges ahead with mission statement for all of pharmacy. Drug Topics 1991, 135:74-75.
19. Fiore MC, Bailey WC, Cohen SJ: Treating Tobacco Use and Dependence. Clinical Practice Guideline. Rockville, Md.: U.S. Department of Health and Human Services. Public Health Service 2000.
20. Smith MD, McGhan WF, Lauger G: Pharmacist counseling and outcomes of smoking cessation. American Pharmacy 1995, NS35(8):20-9.
21. Benowitz NL: Nicotine addiction. Primary Care Clinics in Office Practice 1999, 26(3):611-31.
22. Hansten PD, Horn JR: Drug Interactions: Analysis and Management. Applied Therapeutics Vancouver, WA 2001. (updated regularly)
23. Mistry SK, Sorrentino AP: Patient Non-adherence: The $100 Billion Problem. American Druggist 1999, 216:56-63.
24. Lucas GM, Cheever LW, Chaisson RE, Moore RD: Detrimental Effects of Continuous Illicit Drug Use on the Treatment of HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes 2001, 27(3):251-259.
25. Ewing JA: Detecting Alcoholism: The CAGE questionnaire. JAMA 1984, 252:1905-1907.
26. Brown RL, Leonard T: A Two Item Conjoint Screen for Alcohol and Other Drug Problems. Journal of the American Board of Family Practice 2001, 14:95-106.
27. Williams R, Vinson DC: Validation of a Single Screening Question for Problem Drinking. Journal of Family Practice 2001, 50(4):307-320.
28. Johnson RE, Strain EC, Amass L: Buprenorphine: How to use it right. Drug and Alcohol Dependence 2003, 70:S59-S77.
29. O'Farrell TJ, Fals-Stewart W: Treatment Models and Methods: Family Models. Addictions A Comprehensive Guidebook Volume Chapter 16. Edited by: McCrady BS, Epstein EE. Oxford University Press; 1999.
30. Chassin L, Curran PJ, Hussong AM, Colder CR: The Relation of Parent Alcoholism to Adolescent Substance Use: A Longitudinal Follow-UP Study. Journal of Abnormal Psychology 1996, 105(1):70-80.
31. Sanjuan PM, Langenbucher JW: Age-Limited Populations: Youth, Adolescents, and Older Adults. Addictions A Comprehensive Guidebook Volume Chapter 16. Edited by: McCrady BS, Epstein EE. Oxford University Press; 1999.
32. Knight JR, Shrier LA: A new brief screen for adolescent substance abuse. Arch Pediatr Adolesc Med 1999, 153:591-596.
33. Tommasello AC: The Pharmacology of Alcohol and Street Drugs in the Context of Trauma Care. Trauma Quarterly 2000, 14(4):365-384.
34. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etlinger A, Mechoulam R: Isolation and Structure of a Brain Constituent that Binds to the Cannabinoid Receptor. Science 1992, 258:1946-1949.
35. Aghajanian GK: Serotonin and the Action of LSD in the Brain. Psychiatric Annals 1994, 24(3):137-141.
36. Cedarbaum JM, Aghajanian GK: Activation of locus coeruleus neurons by peripheral stimuli: modulation by a collateral inhibitory mechanism. Life Sciences 1978, 23:1383-1391.
37. McCabe OL: Psychedelic Drug Crisis: Toxicity & Therapeutics. J Psychedelic (Psychoactive) Drugs 1977, 9(2):107-121.
38. Nicholson KL, Balster RL: GHB: a new and novel drug of abuse. Drug and Alcohol Dependence 2001, 63:1-22.
39. Morgan MJ: Ecstasy (MDMA): A Review of its Possible Persistent Psychological Effects. Psychopharmacology 2000, 152:230-248.
40. Green RA, Cross AJ, Goodwin GM: Review of the pharmacology and clinical pharmacology of 2,3-methylenedioxymethamine (MDMA or Ecstasy). Psychopharmacology 1995, 119:247-260.
41. Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, Poland RE: Effect of Ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on Cerebral Blood Flow: A co-registered SPECT and MRI Study. Psychiatry Research Neuroimaging 2000, 98:15-28.
42. McCann UD, Szabo Z, Scheffel U, Dannals RF, Ricaurte GA: Positron Emission Tomographic Evidence of Toxic Effects of MDMA (Ecstasy) on Brain Neurons in Human Beings. Lancet 1998, 352:1433-1437.
43. Chang L, Ernst T, Grob CS, Poland R: Cerebral 1H MRS Alterations in Recreational 3,4,-methylenedioxymethamphetamine (MDMA, "Ecstasy") Users. Journal of Magnetic Resonance Imaging 1999, 10:521-526.
44. Chang L, Grob CS, Ernst T, Itti L, Mishkin FS, Jose-Melchor R, Poland RE: Effect of Ecstasy [3,4-methylenedioxymethamphetamine (MDMA)] on Cerebral Blood Flow: A co-registered SPECT and MRI Study. Psychiatry Research Neuroimaging 2000, 98:15-28.
45. Prochaska JO: Changing for Good New York, William Morrow; 1994.
46. Miller WR, Rollnick S: Motivational Interviewing: Preparing People to Change Addictive Behavior New York, Guilford Press; 1991.
47. Levinson W, Cohen MS, Brady D, Duffy DF: To Change or Not To Change: "Sounds Like You Have a Dilemma.". Annals of Internal Medicine 2001, 135(5):386-391.
48. Roman PM: The Use of EAPs in Dealing With Drug Abuse in the Workplace. NIDA Research Monograph #91 1989:271-286.
49. Penna RP, Williams RL: Helping the Impaired Pharmacist - A Handbook for Planning and Implementing State Programs American Pharmaceutical Association. Washington, D.C 1985.
50. Trinkoff AM, Storr C: Relationship of Specialty and Access to Substance Use Among Registered Nurses: An Exploratory Analysis. Drug and Alcohol Dependence 1994, 36:215-219.
51. Blazer LK, Mansfield PK: A Comparison of Substance Use Rates Among Female Nurses, Clerical Workers and Blue Collar Workers. Journal of Advanced Nursing 1995, 21(2):305-313.
52. Tommasello AC: The Effects of State Policies on Addiction Intervention in the Health Professions: The Case of Pharmacy. Dissertation, University of Maryland 2000.